- Home
- DCTH vs PHAT Comparison
DCTH vs PHAT Comparison
Compare DCTH & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- PHAT
- Stock Information
- Founded
- DCTH 1988
- PHAT 2018
- Country
- DCTH United States
- PHAT United States
- Employees
- DCTH N/A
- PHAT N/A
- Industry
- DCTH Medical/Dental Instruments
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- DCTH Health Care
- PHAT Health Care
- Exchange
- DCTH Nasdaq
- PHAT Nasdaq
- Market Cap
- DCTH 518.0M
- PHAT 423.4M
- IPO Year
- DCTH N/A
- PHAT 2019
- Fundamental
- Price
- DCTH $12.98
- PHAT $5.49
- Analyst Decision
- DCTH Strong Buy
- PHAT Strong Buy
- Analyst Count
- DCTH 4
- PHAT 5
- Target Price
- DCTH $22.75
- PHAT $23.00
- AVG Volume (30 Days)
- DCTH 494.6K
- PHAT 1.6M
- Earning Date
- DCTH 03-06-2025
- PHAT 05-08-2025
- Dividend Yield
- DCTH N/A
- PHAT N/A
- EPS Growth
- DCTH N/A
- PHAT N/A
- EPS
- DCTH N/A
- PHAT N/A
- Revenue
- DCTH $37,205,000.00
- PHAT $55,252,000.00
- Revenue This Year
- DCTH $112.81
- PHAT $202.16
- Revenue Next Year
- DCTH $61.78
- PHAT $113.86
- P/E Ratio
- DCTH N/A
- PHAT N/A
- Revenue Growth
- DCTH 1701.69
- PHAT 8001.47
- 52 Week Low
- DCTH $4.26
- PHAT $4.07
- 52 Week High
- DCTH $16.97
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- DCTH 44.79
- PHAT 46.30
- Support Level
- DCTH $12.18
- PHAT $4.76
- Resistance Level
- DCTH $14.61
- PHAT $6.89
- Average True Range (ATR)
- DCTH 0.77
- PHAT 0.61
- MACD
- DCTH -0.00
- PHAT 0.00
- Stochastic Oscillator
- DCTH 33.47
- PHAT 50.35
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.